Medicinal Cannabis Products, Made in New Zealand

Cannasouth was New Zealand’s first medicinal cannabis company to list on the New Zealand Stock Exchange (NZX:CBD) in June 2019. We are a vertically integrated biopharmaceutical company dedicated to advanced product development and research. Our goal is to develop next-generation medicinal cannabinoid therapeutics for prescribers and patients in New Zealand and export these pharmaceutical quality products and technologies globally.

We will produce our cannabis-based medicines and ingredients using cannabinoid extracts from high-quality, medical-grade cultivars. These medicines will be manufactured under GACP and GMP regulations using environmentally friendly methods, ensuring patients are treated with sophisticated medicines made of pure therapeutic compounds of the highest quality.

Learn more about Cannasouth 


CCL Commissioning complete
Cannabis Science: Medicinal Cannabis for Neuropathic Pain
Cannabis Science: Georgia's Masters Research


medicinal cannabis in New Zealand

Cannasouth provides clinical data, educational material and media for specialists, doctors, and clinicians enabling informed patient treatment choices.

Medicinal Cannabis Prescriber Education

a medicinal cannabis patient in New Zealand

Supporting patient access to high-quality educational material regarding cannabinoid therapeutics is central to meaningful health outcomes.

Medical Cannabis for Patients

investing in medicinal cannabis new zealand

Our investors are critical to the success of the company. We acknowledge the special trust they place in us with our commitment to the expansion of Cannasouth.

More Info for Investors